E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
hypertension artérielle par hyperaldostéronisme primaire |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10039834 |
E.1.2 | Term | Secondary hypertension |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the effects of LCI699 on mean 24-hour systolic blood pressure (SBP) as measured by ambulatory blood pressure monitoring (ABPM) |
|
E.2.2 | Secondary objectives of the trial |
• To examine the safety and tolerability of LCI699 • To explore the effects of LCI699 on plasma and urine hormone levels and electrolytes • To determine the effects of LCI699 on mean 24-hour diastolic blood pressure (DBP) • To determine the effects of LCI699 on mean day time and night time SBP and DBP • To determine the pharmacokinetics of LCI699 following bid dosing
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and/or female subjects 18 to 70 years of age (inclusive) • Female subjects must have been surgically sterilized (oophorectomy with or without hysterectomy) at least 6 months prior to screening. Surgical sterilization procedures must be supported with clinical documentation made available to sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF. OR: • Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion. Menopause will be confirmed by a plasma FSH level of ≥40 IU/L OR: • Male subjects must be using a double-barrier local contraception, i.e., spermicidal gel plus condom, for the entire duration of the study, up to Study Completion visit, and refrain from fathering a child or donating sperm in the three (3) months following last study drug administration. 2. Body mass index of 18 to 34 kg/m2 at Screening. Subjects must weigh at least 50 kg to participate in the study. 3. Diagnosis of primary hyperaldosteronism (PH) within the last 3 years, either with or without an aldosterone producing adenoma (APA). PH will be defined by aldosterone/renin ratio (ARR) ≥ 64 pmol/mU twice and an elevated aldosterone concentration (plasma ≥ 500 pmol/L or urinary ≥63 nmol/day) after 2-6 week washout of drugs interfering with the renin/ angiotensin / aldosterone system (RAAS). 4. Diagnosis of hypertension at screening (systolic and/or diastolic OBP> 140/90 mmHg or on current antihypertensive treatment) 5. Morning plasma cortisol (sampled between 08:00 and 09:00) > 200 nmol/l at screening and 60 min post-ACTH plasma cortisol should be > 500 nmol/l at baseline (Day -15). 6. Able to provide written informed consent prior to study participation. Patient information and consent forms generated by the Investigator must be approved by the sponsor prior to submission to the Institutional Review Board (IRB). A copy of the patient information and consent forms approved by the IRB must be forwarded to the sponsor prior to study initiation. 7. Able to communicate well with the investigator and comply with the requirements of the study. 8. Registration to the French national welfare system
|
|
E.4 | Principal exclusion criteria |
1. Patients with persistent hypokalemia (< 3.0 mmol/l despite oral administration of 6 g/day of KCl) 2. Patients with renal impairment (estimated creatinine clearance < 60 ml/min by the MDRD formula). 3. Use of any medication listed in paragraphe 6.6.5 within the four (4) weeks prior to dosing. 4. Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations. 5. Any blood donation or significant loss within 56 days of first dosing; donation of plasma within 7 days prior to first dosing. 6. Anemia as defined by a hemoglobin level at screening or baseline (Day -15) ≤ 10 g/dl. 7. Malignancy including leukemia and lymphoma (not including basal cell skin cancer) within the last 5 years 8. Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance, but not limited to, any of the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stappling, or gastric banding, currently active inflammatory bowel syndrome. 9. Evidence of significant hepatic disease as determined by any one of the following: a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt, liver disease such as cirrhosis or chronic active hepatitis B and C, any alcohol related hepatic disease 10. Current obstruction of the urinary tract or difficulty in voiding (due to mechanical or inflammatory conditions) that is likely to require intervention during the course of the study, or is regarded as clinically meaningful by the investigator. 11. Any of the following significant laboratory abnormalities: • Clinically significant laboratory abnormalities, confirmed by repeat measurement, other than elevated serum creatinine, hyperglycemia, and glycosuria • Elevated fasting triglycerides > 500 mg/dl at Screening • ALT and AST > 2X upper limit of normal (ULN) • Total bilirubin > 2X ULN • Conjugated bilirubin > 1X ULN • A positive hepatitis B surface antigen (HBsAg) or Hepatitis C test result. 12. History of active substance abuse (including alcohol) within the past 2 years 13. History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures 14. Chronic use of NSAID or COX2 inhibitors or heparin. Aspirin up to 80 mg/day is allowed 15. Chronic use of corticosteroids in any formulation (oral, topical, eye drops, inhaled) 16. Known Keith-Wagener grade III or IV hypertensive retinopathy. 17. History of hypertensive encephalopathy or cerebrovascular accident at any time prior to eligibility visit. 18. Transient ischemic cerebral attack during the 3 months prior to eligibility visit. 19. History of heart failure (NYHA Class I-IV). 20. Unstable angina pectoris or myocardial infarction, or revascularization during the six months prior screening. Stable coronary heart disease patients treated with beta-blockers which cannot be interrupted. 21. Second or third degree heart block without a pacemaker. 22. Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia. Patients with chronic atrial fibrillation (because of the difficulty to measure BP ) 23. Clinically significant valvular heart disease. 24. Type 1 diabetes. 25. Type 2 diabetes mellitus with poor glucose control as defined by HbA1c >8% 26. Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study. 27. History of unreliability or noncompliance to medical regimens or unwillingness to comply with the study protocol. 28. Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety. 29. Persons directly involved in the execution of this protocol.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
to explore the pharmacodynamics (blood pressure, electrolyte and hormonal changes) and safety and tolerability of LCI699 following bid dosing.
ABPM will be used to evaluate the primary endpoint of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 15 |
E.8.9.1 | In the Member State concerned days | 15 |